How Seattle Children’s Therapeutics is Navigating the Pandemic
When the World Health Organization declared COVID-19 a global pandemic in March 2020, Seattle Children’s Therapeutics researcher Kaori Oda worried that her research work would be put on hold, or even worse, need to permanently end. Like most people, she was worried that she and her family might contract the virus, but she was also concerned that a slowdown would impact her team’s timeline for bringing a much-needed therapy to children with leukemia.
Seattle Children’s Therapeutics is a unit in the research division at Seattle Children’s. As a novel non-profit therapeutics development enterprise, it is devoted to envisioning and testing next-generation cell and gene therapies for pediatric diseases, so children have the medicines they deserve.
The Seattle Children’s Therapeutics team has designed, manufactured and launched a robust portfolio of cellular immunotherapy clinical trials for childhood cancer since 2012 in the areas of leukemia, lymphoma, brain tumors and solid tumors. The team plans to expand its focus to other childhood diseases that are amenable to treatment using genetic and cellular therapies. Read full post »